Last update 25 Mar 2025

Diroximel fumarate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Diroximel fumarate (USAN/INN), DRF, ALKS-8700
+ [5]
Target
Action
stimulants
Mechanism
Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (29 Oct 2019),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC11H13NO6
InChIKeyYIMYDTCOUQIDMT-SNAWJCMRSA-N
CAS Registry1577222-14-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Sclerosis, Relapsing-Remitting
European Union
15 Nov 2021
Multiple Sclerosis, Relapsing-Remitting
Iceland
15 Nov 2021
Multiple Sclerosis, Relapsing-Remitting
Liechtenstein
15 Nov 2021
Multiple Sclerosis, Relapsing-Remitting
Norway
15 Nov 2021
Multiple Sclerosis
Switzerland
20 Sep 2021
Multiple sclerosis relapse
United States
29 Oct 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Gangliosidosis, GM1Phase 3
United States
10 Dec 2015
Gangliosidosis, GM1Phase 3
United States
10 Dec 2015
Gangliosidosis, GM1Phase 3
Belgium
10 Dec 2015
Gangliosidosis, GM1Phase 3
Belgium
10 Dec 2015
Gangliosidosis, GM1Phase 3
Bulgaria
10 Dec 2015
Gangliosidosis, GM1Phase 3
Bulgaria
10 Dec 2015
Gangliosidosis, GM1Phase 3
Canada
10 Dec 2015
Gangliosidosis, GM1Phase 3
Canada
10 Dec 2015
Gangliosidosis, GM1Phase 3
Germany
10 Dec 2015
Gangliosidosis, GM1Phase 3
Germany
10 Dec 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
srazsmvuce(bgwsxapkjr) = luivsqqkrg wuyatymsle (xipupeziqt )
Positive
27 Jun 2024
Phase 3
1,057
fsaesysxoz(axywapmbom) = hicbmrtgtv hoqjmjsmqz (scguozjmii )
Positive
15 Jun 2024
Dimethyl fumarate
fsaesysxoz(axywapmbom) = mqqhxbzsor hoqjmjsmqz (scguozjmii )
Not Applicable
-
Fumarates
(Black)
ozpgnwsjrb(rcrhscjghv) = zxkjjpaksw ffsewlawum (bcqgpnifyx, 73.7–80.3)
-
09 Apr 2024
Fumarates
(Hispanic)
ozpgnwsjrb(rcrhscjghv) = vsvjjacqdu ffsewlawum (bcqgpnifyx, 71.0–80.0)
Not Applicable
-
Fumarates
(Black)
zlblqjzavw(visgraapjp) = rmjxenthba xtgkljbsdx (ykkswqtprc )
-
01 Mar 2024
Fumarates
(Hispanic)
zlblqjzavw(visgraapjp) = psfgnkoaav xtgkljbsdx (ykkswqtprc )
Not Applicable
29
ofiwoqjedk(stdeaghofe) = The incidence of lymphopenia (ALC <910) in this cohort of PwMS who transitioned from DMF to DRF increased from 24% at baseline to 52% 12 months after treatment change. jeotuchxjr (qubbmzlheu )
Positive
01 Oct 2023
Not Applicable
-
Diroximel fumarate (DRF)
einloxywvw(pzdolgmskx) = significantly reduced IFNγ secretion in splenocytes isolated from DRF treated mice wnkrzdmsmf (rkfkywbdrf )
Positive
30 Sep 2023
Vehicle (methocel)
Not Applicable
72
hejaxyfzxk(rjdpsyyknl) = mjprmicpjf yyqoxgfzoi (gvhaipzmom )
-
30 Sep 2023
Diroximel Fumarate (DRF)
hejaxyfzxk(rjdpsyyknl) = apnmwzunrb yyqoxgfzoi (gvhaipzmom )
Not Applicable
11
sewggagydj(bqutniizeb) = bionomxift kohpujpynb (irmlkogoga )
Positive
30 May 2023
sewggagydj(bqutniizeb) = tkughmvvor kohpujpynb (irmlkogoga )
Phase 3
-
afgxqvwhnz(exwotvejxt): risk ratio = 0.924 (95% CI, 0.646 - 1.324)
Positive
30 May 2023
Phase 3
-
yaizkoiaeh(gcowjyenhz) = qjhqphnfzh foiorzaaou (iiapebnazt )
-
08 May 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free